Novartis has released new data on five-year long-term immunogenicity and integrative clinical analysis that confirmed its comprehensive interstitial-17A inhibitor Cosentyx's effect on psoriasis.
|Novartis' psoriasis treatment Cosentyx|
"This is the first time that the company analyzed the efficacy and safety data from the dedicated phase 3 trials in one abstract, backing Cosentyx as comprehensive treatment across multiple manifestations of psoriatic disease and ankylosing spondylitis," the company said.
The abstract presented recently at the World Congress of Dermatology in Milan shows the long-term efficacy and safety of Cosentyx in multiple manifestations of psoriatic disease including moderate-to-severe plaque-type, nail and palmoplantar psoriasis, psoriatic arthritis and ankylosing spondylitis, the company said.
Proven efficacy of treatments in persistent manifestations of nails, scalp and palmoplantar psoriasis is a specific concern for patients as these are significantly reducing the quality of life and are impacting up to nine out of every 10 psoriasis patients.
Additional five-year data with Cosentyx confirmed low immunogenicity with rates year over year consistently below 1 percent in patients with moderate to severe plaque psoriasis.
The company has conducted 100 studies on the treatment, proving it offers clear or almost clear skin in eight of 10 patients within 16 weeks of treatment.
"Up to nine out of every 10 patients with psoriasis experience symptoms manifested by various aspects such as nails, hands, and feet, and experience a decrease in quality of life," said Joseph Liu, executive director of Cosentyx franchise at Novartis Korea. "Cosentyx will present a comprehensive therapeutic approach to psoriasis based on its 100 robust clinical trials and more than 200,000 prescription experiences worldwide."
<© Korea Biomedical Review, All rights reserved.>